DENTSPLY SIRONA Inc. designs, develops, manufactures, and markets various dental products and technologies, and other consumable dental products and equipment primarily for the professional dental market worldwide. More Details
No risks detected for XRAY from our risk checks.
Adequate balance sheet with moderate growth potential.
Share Price & News
How has DENTSPLY SIRONA's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: XRAY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: XRAY's weekly volatility (6%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: XRAY underperformed the US Medical Equipment industry which returned 16.3% over the past year.
Return vs Market: XRAY underperformed the US Market which returned 19.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is DENTSPLY SIRONA's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 months ago | Simply Wall StAre DENTSPLY SIRONA's (NASDAQ:XRAY) Statutory Earnings A Good Reflection Of Its Earnings Potential?
7 months ago | Simply Wall StAre DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Mixed Financials Driving The Negative Sentiment?
8 months ago | Simply Wall StOnly 4 Days Left To Cash In On DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Dividend
Is DENTSPLY SIRONA undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: XRAY ($51.32) is trading below our estimate of fair value ($57.01)
Significantly Below Fair Value: XRAY is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: XRAY is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: XRAY is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate XRAY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: XRAY is good value based on its PB Ratio (2.4x) compared to the US Medical Equipment industry average (4.4x).
How is DENTSPLY SIRONA forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XRAY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: XRAY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: XRAY's is expected to become profitable in the next 3 years.
Revenue vs Market: XRAY's revenue (7.7% per year) is forecast to grow slower than the US market (10.2% per year).
High Growth Revenue: XRAY's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: XRAY's Return on Equity is forecast to be low in 3 years time (10.3%).
How has DENTSPLY SIRONA performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XRAY is currently unprofitable.
Growing Profit Margin: XRAY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XRAY is unprofitable, and losses have increased over the past 5 years at a rate of 16.6% per year.
Accelerating Growth: Unable to compare XRAY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XRAY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.2%).
Return on Equity
High ROE: XRAY has a negative Return on Equity (-1.66%), as it is currently unprofitable.
How is DENTSPLY SIRONA's financial position?
Financial Position Analysis
Short Term Liabilities: XRAY's short term assets ($2.6B) exceed its short term liabilities ($1.2B).
Long Term Liabilities: XRAY's short term assets ($2.6B) do not cover its long term liabilities ($3.0B).
Debt to Equity History and Analysis
Debt Level: XRAY's debt to equity ratio (46.7%) is considered high.
Reducing Debt: XRAY's debt to equity ratio has reduced from 50.7% to 46.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable XRAY has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: XRAY is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 0.5% per year.
What is DENTSPLY SIRONA current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: XRAY's dividend (0.78%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.47%).
High Dividend: XRAY's dividend (0.78%) is low compared to the top 25% of dividend payers in the US market (4.05%).
Stability and Growth of Payments
Stable Dividend: XRAY's dividends per share have been stable in the past 10 years.
Growing Dividend: XRAY's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: XRAY is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of XRAY's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Don Casey (60 yo)
Mr. Donald M. Casey, Jr., also known as Don, serves as CEO and Director at DENTSPLY International Inc., since 2018. Mr. Casey has been Chief Executive Officer and a Director at Dentsply Sirona Inc. since ...
CEO Compensation Analysis
Compensation vs Market: Don's total compensation ($USD11.37M) is about average for companies of similar size in the US market ($USD10.79M).
Compensation vs Earnings: Don's compensation has increased whilst the company is unprofitable.
|CEO & Director||2.75yrs||US$11.37m||0.045% |
|Executive VP & CFO||1.25yrs||US$10.30m||0.016% |
|Executive VP||3.08yrs||US$4.61m||0.0037% |
|Senior VP & Chief Commercial Officer||3.33yrs||US$3.11m||0.020% |
|Chief Accounting Officer||0.25yr||no data||no data|
|Senior VP & Chief Technology Officer||1.5yrs||no data||0.0018% |
|Vice President of Investor Relations||no data||no data||no data|
|Senior VP and Chief HR Officer & Communications||1.08yrs||no data||0.0022% |
|Senior VP||1.5yrs||no data||0.0049% |
|Senior Vice President||11.83yrs||US$1.35m||no data|
|Chief Clinical Officer & VP||no data||no data||no data|
|Senior Vice President of EMEA RCO||3.33yrs||US$1.52m||0.012% |
Experienced Management: XRAY's management team is considered experienced (2.1 years average tenure).
|CEO & Director||2.75yrs||US$11.37m||0.045% |
|Independent Director||15.5yrs||US$326.95k||0.012% |
|Independent Non-Executive Chairman||3.17yrs||US$517.03k||0.013% |
|Director||0.17yr||no data||no data|
|Independent Director||4.75yrs||US$278.57k||0.059% |
|Independent Director||2.83yrs||US$321.32k||0.0042% |
|Independent Director||19.75yrs||US$271.25k||0.0050% |
|Independent Director||2.83yrs||US$278.75k||0% |
|Independent Director||1.5yrs||US$256.42k||0.0061% |
|Independent Director||4.75yrs||US$267.50k||0.019% |
|Independent Director||9.75yrs||US$283.75k||0.0069% |
|Independent Director||1.17yrs||US$162.13k||no data|
Experienced Board: XRAY's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
DENTSPLY SIRONA Inc.'s company bio, employee growth, exchange listings and data sources
- Name: DENTSPLY SIRONA Inc.
- Ticker: XRAY
- Exchange: NasdaqGS
- Founded: 1899
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$11.216b
- Shares outstanding: 218.56m
- Website: https://www.dentsplysirona.com
Number of Employees
- DENTSPLY SIRONA Inc.
- 13320 Ballantyne Corporate Place
- North Carolina
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|XRAY||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Aug 1987|
|DY2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 1987|
|0I8F||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Aug 1987|
|XRAY||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Aug 1987|
|DY2||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Aug 1987|
|XRAY *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Aug 1987|
|XRAY34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH REP 1 COM USD0.01||BR||BRL||May 2019|
DENTSPLY SIRONA Inc. designs, develops, manufactures, and markets various dental products and technologies, and other consumable dental products and equipment primarily for the professional dental market w...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/26 23:24|
|End of Day Share Price||2020/11/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.